Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Oct 23, 2023 7:10pm
162 Views
Post# 35697319

Tolerance, drug interactions, simplification..

Tolerance, drug interactions, simplification..

Increasing and changing pattern of treatment switches among people with HIV

This is quite useful information! As it mentioned in the article there are more patients altering their regimen lately due to availability of newer and safer drugs. The HIV combo therapies' primarily goal is to keep viral load low enough in order to prevent AIDS and there are many combinations of various classes of drugs however many of these drugs are not tolerated due to toxicities and have drug interactions/adverse effects. As per this recent study in 2021/2022 among almost 11 thousand patients some 1000 of them changed their regimen(18 percent). 37 percent due to toxicity, 33 percent due side effects and only 17 percent due simplification. The recent PR about cost effectiveness of Trogarzo which is generally well tolerated and have fewer side effects/drug interactions compared to other HIV  drugs should be considered not only by payers but patients and their doctors. Point is only 3 percent of switches were due to lack of efficiency that's why the overall therapeutic profile of Trogarzo should be a significant part of the education of patients and their caregivers.

As per PR:

"The analysis encompassed numerous costs, including those for treatment acquisition and administration, monitoring, adverse events, opportunistic infections, and terminal care."

So the cost/ concerns of any medical treatment includes not only the treatment but also dealing with other costly issues it can cause and those issues seems to be a rather meaningful concern among HIV patients battling with many co-morbidities resulting in changing their regimen.

<< Previous
Bullboard Posts
Next >>